Sandra Tuyaerts

11PUBLICATIONS
37CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 26, 2026
Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrative Review.

|Nov 19, 2024
Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity.

Fien Meeus, Cyprine Neba Funeh, Robin Maximilian Awad

|Jan 11, 2024
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.

Jens Tijtgat, Xenia Geeraerts, Anais Boisson

|Aug 27, 2021
Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?

Regina Esi Mensimah Baiden-Amissah, Daniela Annibali, Sandra Tuyaerts

|Apr 30, 2021
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

Wout De Wispelaere, Daniela Annibali, Sandra Tuyaerts

|Nov 13, 2020
Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial.

Julia Katharina Schwarze, Gil Awada, Louise Cras

Pageof 2

Frequent Collaborators

3 joint publications

Julia Katharina Schwarze

3 joint publications

Daniela Annibali

2 joint publications

Bart Neyns

2 joint publications

Regina Esi Mensimah Baiden-Amissah